Latest Breaking News On - ஹடாஸா மருத்துவ ஆர்கநைஸேஶந் - Page 5 : comparemela.com

Share this article REHOVOT and JERUSALEM , Israel, April 6, 2021 /PRNewswire/ MyBiotics Pharma Ltd. http://biomx.com/, a microbiome therapeutics company, and Hadasit Medical Research Services and Development Ltd., the technology transfer office of Hadassah Medical Center, announced today that they have entered into a research collaboration and licensing agreement for the identification of microbiome-based therapeutics that will enhance the response to and reduce adverse effects of anti-PD-1 and anti-PD-L1 in melanoma patients. The collaboration will combine Hadassah s knowhow and expertise in immunotherapy treatment of melanoma patients with MyBiotics proprietary microbiome technologies enabling development of novel therapeutics. The two-year joint research project will be conducted by researchers from MyBiotics together with a team of researchers at Hadassah Cancer Research Institute headed by Prof. Michal Lotem, MD., Head of the Center for Melanoma and Cancer Immunotherapy,

Israel generalTsipi haitovskyItamar razMichal lotemMybiotic superdonorKfir umanskyDavid daboushMybiotics pharmaHadar elboimHadasit medical research servicesHadassah medical centerMybiotics pharma ltdHadassah medical organizationDepartment of oncology at hadassah medical centerHadassah cancer research instituteDevelopment ltd